e-Article
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
Document Type
Article
Author
Source
In Gynecologic Oncology March 2018 148(3):507-514
Subject
Language
ISSN
0090-8258